Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
This article was originally published in PharmAsia News
Executive Summary
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder